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Introduction: The effect of neoadjuvant chemotherapy (NAC) on the expression of receptor status in
locally advanced breast cancer (LABC) is still under investigation. Aims of this study are to evaluate
changes in hormone receptor (HR) and HER-2 status post-NAC and correlation with survival.
Materials and methods: LABC patients who received NAC between 2001 and 2008 at Istanbul University
were analyzed retrospectively. Patients with pathologic complete response (pCR) were excluded in
analysis. Immunohistochemical (IHC) analyses was performed on both initial biopsies and surgical
specimens.
Results: The median age of 128 patients was 48 years and 55% of themwere premenopausal. Most of the
patients had invasive ductal (81%) and histologic grade (HG) III (81%) breast cancer. Partial pathologic
response (pPR) rate was 86.7%. HR status changed in 36 patients (28%). The rates of ER, PR and HER-2
receptor positivity at diagnosis and after NAC were 44–32.8%, 43–29.7%, and 24–21%, respectively. Ne-
gative-to-positive change in HR status was observed in ﬁve patients. The 5-year overall survival (OS) was
76% in patients whose HR status converted to negative, compared with 91% in patients who remained
HR-positive (po0.05). Multivariate Cox regression analysis showed that receptor status change was
independently related to disease-free survival (DFS) (Hazard Ratio 6.88; p¼0.002), whereas as it did not
have any impact on OS (p¼0.148).
Conclusion: NAC induced changes in HR and HER-2 expression, predominantly from positive to negative.
These changes were associated with shorter DFS. Postoperative re-evaluation of receptor status may have
clinical signiﬁcance.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is the most common cancer among women in
both developed and developing countries, including Turkey [1,2].
Locally advanced breast cancer (LABC) rate is high in low- and
middle-income countries due to deﬁciencies in mammographic
screening, breast cancer awareness and health care infrastructure.
Neoadjuvant chemotherapy (NAC) is the recommended systemicLtd. This is an open access article u
n@yahoo.com.tr (V. Ozmen),
mail.com (A. Bozdogan),
om (Y. Eralp),
B, 1200 Brussels, Belgium.treatment approach for LABC [3–5] .The major aims of primary
systemic therapy in these patients are to eradicate possible distant
micrometastatic disease and to increase breast-conserving ther-
apy. NAC also allows assessment of tumor sensitivity to systemic
treatment. Pathologic complete response to NAC carries prognostic
signiﬁcance independent of other common prognostic biologic
markers [6].
Hormonal receptors and Human Epidermal Growth Factor Re-
ceptor 2 (HER-2) receptor were the ﬁrst biomarkers recommended
for routine clinical use and to this day, they have utmost im-
portance in treatment planning [7,8]. The indications for targeted
therapies against the Estrogen Receptor (ER), Progesterone Re-
ceptor (PR) and HER-2 are traditionally based of initial tumor
characteristics. ER, PR and HER2 receptors along with the pro-
liferative marker Ki 67 can also serve as surrogates to helpnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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oncology, such as luminal A [4,9]. They also have predictive value,
providing valuable information for estimating response to differ-
ent types of treatment. Strong ER expression often predicts a good
response and good clinical outcomes with anti-estrogen therapy.
On the other hand, the strength of ER expression has been shown
to correlate negatively with chemotherapy response and pCR rates
after NAC [10,11]. HER-2 is over-expressed in 10–25% of breast
cancers and is associated with a more aggressive form of cancer
[12,13].
Changes in ER, PR and HER2 receptor status following NAC have
been previously reported [14–17]. In a systematic review, HR and
HER2 status was found to have changed after neoadjuvant sys-
temic therapy in 51% and 43% of patients, respectively [15]. There
is an ongoing debate about the rate and the signiﬁcance of re-
ceptor status change and the implications for subsequent adjuvant
systemic therapy. Moreover, prognostic implications of the NAC
effect on these receptors have not been thoroughly studied. The
purpose of this study was to investigate the concordance rate of
HR and HER-2 receptor status before and after NAC, as well as the
relationship between survival and changes in receptor in patients
with LABC.2. Patients and methods
2.1. Patient population
Following institutional review board approval, the study team
retrospectively identiﬁed 322 patients with LABC who were trea-
ted with neoadjuvant anthracycline- and/or taxane-based che-
motherapy between 2001 and 2008 at the Breast Unit of the De-
partment of Surgery at Istanbul Medical Faculty. Our standard
approach is to recommend neoadjuvant chemotherapy to patients
with initial clinical stage IIB-IIIC disease, therefore only this group
of patients were included the study. Only patients who had initial
pathologic testing at our center and had residual tumor were in-
cluded. Patients with insufﬁcient tumor tissue in post-surgical
material, either due to complete pathological response or an in-
sufﬁcient number of remaining tumor cells, and patients who lost
regular follow-up and patients with primary inﬂammatory carci-
noma were excluded. Post-surgical HR and HER-2 receptor status
analyses were performed on the tumor samples of 128 patients by
dedicated breast cancer pathologists.
2.2. Diagnostic evaluation
The baseline workup included clinical examination, bilateral
mammography, breast ultrasound and magnetic resonance ima-
ging (MRI). After physical examination and radiologic studies
(mammography, ultrasonography, MRI), core (n¼190, 59%) or in-
cisional biopsies (n¼132, 42%) were performed for histopathologic
diagnosis. When invasive adenocarcinoma was demonstrated, the
tumor grade was determined using the Scarff–Bloom–Richardson
(SBR) grading system.
Chest radiography, abdominal ultrasonography, bone scinti-
graphy, computed positron emission tomography (PET-CT), thorax
and abdominal computed tomography (CT) were among the
modalities that were used in systemic staging to look for distant
metastasis.
2.3. Determination of HR and HER-2 status
Tumor samples were compared when available for the analysis
of HR and HER-2 status of the tumor. The ﬁrst biopsy was a needle
core or incisional performed before NAC. The second sample camefrom the remaining tumor in the surgical specimen following
breast surgery. All immunohistochemical (IHC) analyses for HER-2,
ER and PR were carried out in a single reference laboratory and
evaluated by light microscopy independently by dedicated breast
pathologists, who were blinded to patient identiﬁers and patient
history. The general protocol for IHC staining is detailed below in
section 2.5.
2.4. . Treatment modalities
Patients were treated with one of the two following neoadju-
vant chemotherapy protocols: (1) FAC or FEC (ﬂuorouracil, adria-
mycin/epirubicin, cyclophosphamide) for 6 cycles, or (2) AC
(adriamycin and cyclophosphamide) for 4 cycles followed by
docetaxel (T) for 4 cycles. Chemotherapy was administrated in-
travenously at 21-day intervals. After systemic treatment, patients
underwent appropriate surgery, radiation therapy, and hormonal
therapy if HR was positive at any time-point. Trastuzumab was not
used due to the lack of insurance coverage for non-metastatic
patients in our country until 2009.
Surgery was performed approximately 1 month after the ﬁnal
cycle of chemotherapy. All patients received adjuvant radiation
therapy. Patients who had a positive IHC for ER and/or PR at any
time-point were treated with hormonal therapy regardless of any
change in their HR receptor status.
2.5. Pathological evaluations and statistical analysis
2.5.1. Response assessment
The patients who had no remaining invasive cancer in the
breast (ypT0) and who were lymph node negative (ypN0) were
considered to have a pathological complete response (pCR). The
tumor response to neoadjuvant chemotherapy was evaluated pa-
thologically by classifying the regressive changes using a semi-
quantitative scoring system from 0 to 4 (0¼no effect,
1¼resorption and tumor sclerosis, 2¼minimal residual invasive
tumor [o0.5 cm], 3¼residual non-invasive tumor only, 4¼no
tumor detectable) according to the tumor regression grading de-
scribed by Sinn et al. [18].
2.5.2. Immunohistochemical technique and statistical models
Immunohistochemical analyses (IHC) were performed on both
initial biopsies and also surgical resection specimens for each
patient. The tissue was ﬁxed in 4.5% buffered formalin (pH 7.0) and
embedded in parafﬁn. The IHC was performed on 3–5 μm thick
sections mounted on poly-L-lysine slides using a commercially
available ABC kit (Vectastain, Vector Laboratories, Burlingame, CA,
USA). The primary antibodies were diluted in Tris–HCl (pH 7.5)
and applied according to the manufacturer’s instructions. DAB
(3,3′diaminobenzidine) was used as chromogen. Finally, the slides
were counterstained with Mayer's hematoxylin for 10 s and
mounted for examination. For assessment of the proliferation in-
dex (Ki-67), p53 expression, ER and PR status, the percentage of
cells with nuclear reactivity was recorded. For both ER and PR
expression, 41% was considered to be positive. For HER-2 ex-
pression, only membranous staining was evaluated. HER-2 ex-
pression was then scored semi-quantitatively using the 0–3þ
score (0: no staining or membrane staining in o10% of tumor
cells, 1þ: 410% of tumor cells with weakly positive incomplete
membrane staining, 2þ: 410% of tumor cells with weak to
moderate staining of the entire membrane, 3þ: 410% of tumor
cells with strong staining of the entire membrane).
Statistical analyses were performed using SPSS 17.0 for Win-
dows software (SPSS Inc., Chicago, IL, USA). The associations be-
tween ordinal variables were assessed using Pearson Chi-Square,
Continuity Correction or the Fisher Exact Test in the case of 22
Table 1
Patients and tumor characteristics.
Characteristic A (90, 70%) AþT (38,
30%)
Overall p Value
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and survival differences were analyzed by the log-rank test. Cox
regression analysis was performed to test the effect of major
prognostic factors on overall survival (OS) and disease-free survi-
val (DFS).Median age 47.5 (25–74) 48.5 (31–76) 48.0 (25–76) 0.818
Menopausal status 0.913
Premenopausal 50 (55.6%) 20 (52.6%) 70 (54.7%)
Postmenopasal 40 (44.4%) 18 (47.4%) 58 (44.3%)
Stage (before NAC) 0.227
IIB 15 (16.7%) 12 (31.6%) 27 (21.1%)
IIIA 42 (46.7%) 16 (42.1%) 58 (45.3%)
IIIB 31 (34.4%) 10 (26.3%) 41 (32.0%)
IIIC 2 (2.2%) 0 (0.0%) 2 (1.6%)
Pathology 0.654
Invasive ductal 72 (80.0%) 32 (84.2%) 104 (81.3%)
Invasive lobular 5 (5.6%) 3 (7.9%) 8 (6.3%)
Other 13 (14.4%) 3 (7.9%) 16 (12.5%)
SBR grade 0.094
II 13 (14.4%) 11 (28.9%) 24 (19.0%)
III 77 (85.6%) 27 (70.1%) 104 (81.0%)
Estrogen receptora 0.262
Positive 36 (40.0%) 20 (52.6%) 56 (44.0%)
Negative 54 (60.0%) 18 (47.4%) 72 (56.0%)
Progesterone receptora 0.103
Positive 34 (37.8%) 21 (55.3%) 55 (43.0%)
Negative 56 (62.2%) 17 (44.7%) 73 (57.0%)
HER-2 receptora 0.893
Positive 21 (23.3%) 10 (26.3%) 31 (24.0%)
Negative 69 (76.7%) 28 (73.7%) 97 (76.0%)
Surgery 0.172
BCS 11 (12.2%) 9 (23.7%) 20 (15.6%)
Mastectomy 79 (87.8%) 29 (76.3%) 108 (84.4%)3. Results
3.1. Patient characteristics
Fig. 1 outlines the patient selection process. Table 1 shows the
main clinico-pathological characteristics of the patients included
in this study. Median age was 48 years (25–76), and 55% of pa-
tients were premenopausal. Lymph node involvement was noted
in 57% of the patients before systemic treatment. 21% of patients
had stage IIB, 79% had stage III breast cancer. The predominant
tumor type was invasive ductal carcinoma (71%) followed by lob-
ular carcinoma in 19% of the cases. 81% patients had invasive
ductal and grade III breast cancer. The HR positivity rates were 44%
for ER and 43% for PR. 24% patients had HER-2 positive disease.
Clinically, out of the 128 patients treated with neoadjuvant
chemotherapy, stable disease (SD) or progression of disease (PD)
was observed in 17 patients and ﬁve patients, respectively. In
terms of pathologic response, partial response (pPR) was seen in
111 patients (87%). Breast-conserving surgery (BCS) rate was 15.6%.
3.2. Expression of hormone receptors and HER2
Table 2 outlines the status of hormone receptors in the diag-
nostic “baseline” biopsies and post-chemotherapy surgical speci-
mens. The expression of ER was assessed in all 128 pre- and post-
NAC sample pairs and remained the same in 113 (86%) sample
pairs. One initially ER negative tumor became ER positive and 14
(11%) initially ER positive tumors became ER negative after che-
motherapy. The difference in ER expression level before and after
chemotherapy exposure was not statistically signiﬁcant (p40.05).
PR expression was also determined in all 128 pre- and post-322 eligible patients identified (NAC and surgery at 
Istanbul Medical Faculty)
128 patients with evaluable samples 
both before NAC and after surgery 
were included in final analysis
194 were excluded:
95 due to inadequate material
48 due to pCR 
15 due to inflammatory breast 
cancer
36 lost to follow up
Fig. 1. Flow chart of patient' selection process.
Pathologic response 0.392
Partial Response 76 (84.4%) 35 (92.1%) 111 (86.7%)
Minor Response/Stable 14(15.6%) 3 (7.9%) 17 (13.3%)
Lymphovascular
invasion
0.040a
Positive 55 (61.1%) 15 (39.5%) 70 (54.7%)
Negative 35 (38.9%) 23 (60.5%) 58 (45.3%)
Adjuvant treatment
Chemotherapy 47 (52.2%) 14 (36.8%) 61 (47.7%) 0.162
Radiation therapy 90 (100.0%) 38 (100,0%) 128 (100.0%) –
Hormonotherapy 38 (42.2%) 23 (60.5%) 61 (47.7%) 0.089
A: anthracycline based regimen; AþT: anthracyclineþtaxane based regimen; BCS:
breast-conserving surgery.
po0,05; Chi-Square tests (Pearson Chi-Square, Continuity Correction, Fisher's Ex-
act test).
a ER, PR and HER2 results represent receptor status at initial diagnosis.chemotherapy sample pairs and no change in expression was
observed in 107 (84%). A switch from PR negative before to PR
positive post-chemotherapy was detected in 3% and from PR po-
sitive to negative in 13%.
HER-2 expression by IHC remained unchanged in 124 out of
128 sample pairs. In four patients (%3), HER-2 expression switched
from positive to negative after NAC.
Table 2
Baseline and post-treatment hormone receptor status.
Change in estrogen receptor status following NAC
Pre-NAC/post-NAC n %
ERþ/ER 14 10, 9
ERþ/ERþ with lower % score 15 11, 7
ER/ERþ 1 0, 8
ERþ/ERþ 26 20, 3
ER/ER 72 56, 3
Change in progesterone receptor status following NAC
Pre-NAC/post-NAC n %
PRþ/PR 17 13, 3
PRþ/PRþ with lower % score 14 10, 9
PR/PRþ 4 3, 1
PRþ/PRþ 20 15, 6
PR/PR 73 57, 0
Table 3
Changes in HR in relation to different NAC protocols.
Type
of
NAC
Hormone
receptor
n Change in hormone re-
ceptor pre-/post-NAC
Change (%) p Value
Neg–
Neg
(%)
Pos–
Pos
(%)
Neg–
Pos
(%)
Pos–
Neg
(%)
A ER 90 60.0 25.6 0.0 14.4 14.4 0.015n
AþT ER 38 47.4 47.4 2.6 2.6 5.2
A PR 90 62.2 20 2.2 15.6 17.8 0.040n
AþT PR 38 44.7 42.1 5.3 7.9 13.2
NAC: neo-adjuvant chemotherapy, A: anthracycline based regimen, AþT: anthra-
cyclineþtaxane based regimen, ER: estrogen receptor, and PR:progesterone
receptor.
n po0,05; Chi-Square test.
Fig. 2. Overall survival in groups according to change in ER.
Fig. 3. Overall survival in groups according to change in PR.
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In the group of patients that received anthracylines alone (FAC/
FEC without taxanes; group A), 14% had ER status change from
positive to negative (p¼0.015; Table 3). On the other hand, in the
patients who received both anthracyclines and taxanes (AC fol-
lowed by docetaxel; group B), only 2.6% had a switch fromER-positive to ER-negative. PR expression change from positive-to-
negative was seen at a rate of 17.8% in group A and 13% in group B
(p¼0.040). Rate of switching from negative-to-positive were low
in both groups (3% in group A, 5% in group B).
3.4. Correlation between different hormone receptors
Signiﬁcant correlations of the expression were observed for ER
and PR (po0.01). For ER and PR, 36 tumors changed the expres-
sion of either or both receptors (28%). Thirteen tumors did not
have a difference in the expression of ER, but switched from PR
positive to PR negative after NAC (36%).
3.5. Disease-free survival and overall survival
In cases without ER expression in both pre- and post-NAC
analyses, the 5- and 10-year overall survival (OS) rates were 66.4%
and 50%, respectively (Group I; stable negative, Fig. 2).
For those cases that showed ER positivity pre-NAC and lost ER
expression after NAC (Group 2; ERþ/ER), the 5- and 10-year OS
rates were 76.0% and 50.0%, respectively.
However, it was noted that if ER expression stayed positive
after NAC, with the strength of expression being either equal to or
higher than pre-NAC analysis, the 5- and 10-year OS rates re-
mained the same (Group 3; stable positive). Moreover, there was a
statistically signiﬁcant difference between the three groups de-
scribed above. (Log-rank test¼p¼0.003).
A similar difference was noted between groups divided ac-
cording change in PR expression in a similar fashion. Patients
whose PR status changed from positive to negative after NAC
(Group 2; PRþ/PR), and patients whose PR expression either did
not change or increased had statistically different OS rates(Log-
rank test¼7.352; p¼0.025).
The median OS was 89.69 months (95%CI: 81.08–98.31). In the
group that did not express ER both pre-NAC and post-NAC, the
median OS was 79,5475,7months. For those cases that showed
ER positivity before NAC and lost ER expression after NAC, the OS
was 88.4178.16 months. In the group that remained ER positive
after NAC, the OS was 94.5473.29 months.
The 10-year OS rate was highest groups with unchanged ER
status and with the switch in the positive direction (ER/ERþ),
whereas the survival was much poorer in the group with loss in ER
expression (ERþ/ER)(p¼0.003; Fig. 2). Similar results were
Table 4
The effect of patient and baseline tumor characteristics on overall and disease free Survival – Univariate analysis.
Factors 10-Year DFS (%) X² p 10-Year overall survival (%) X² p
Age, years 4.206 0.040n 2.912 0.088
o40 42.6 45.4
Z40 60.0 64.2
Menopausal status 1.963 0.161 0.768 0.381
Premenopausal 50.7 60.5
Postmenopasal 60.4 60.2
Stage (Before NAC) 4.017 0.134 6.576 0.037n
IIB 65.1 85.5
IIIA 58.6 63.8
IIIB-C 44.8 44.1
Surgery 0.775 0.379 0.168 0.682
BCS 73.8 75.6
Mastectomy 52.9 59.3
Pathology 0.645 0.422 1.110 0.292
Invasive ductal 53.5 56.8
Other 63.6 76.6
SBR grade 3.034 0.082 3.377 0.066
II 58.5 80.9
III 40.2 60.0
Estrogen receptor 6.122 0.013n 7.187 0.007n
Positive 65.0 74.3
Negative 45.6 48.9
Progesterone receptor 0.007 0.935 2.148 0.143
Positive 57.5 68.2
Negative 56.5 53.6
HER-2 receptor 0.029 0.866 2.577 0.108
Positive 58.8 78.5
Negative 54.5 55.8
Subtype 0.999 0.607 7.604 0.022n
Lum-A/B 61.7 70.8
HER-2 52.4 71.3
TNBC 53.3 46.2
Pathologic response 0.119 0.730 0.000 0.984
Partial Response 56.0 59.0
Minor/Stable Disease 49.4 61.8
Lymphovascular invasion 13.936 o0.001n 16.408 o0.001n
Positive 37.8 43.9
Negative 76.5 82.7
Chemotherapy 3.717 0.054 3.247 0.072
AþT 73.6 76.0
A 50.7 56.8
NAC: Neoadjuvant chemotherapy, BCS: Breast-conserving surgery, A:Anthracycline based regimen, AþT: Anthracyclineþtaxane including regimen.
X2¼Kaplan-Meier Survey Analysis, Log Rank (Mantel-Cox) test.
n po0.05
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the group that showed a switch from negative to positive PR ex-
pression, 10-year OS was high, whereas lowest OS was see in the
group with PR negative status both pre- and post-NAC (p¼0.025;
Fig. 3). The results were similar when the two hormone receptors
were evaluated in combination. Survival was poorer in the HRþ/
group, in contrast to the HR/þ group.The effect of patient and tumor characteristics on DFS and OS
was explored with both univariate and multivariate analysis (Ta-
bles 4 and 5). Any receptor status change was found to be in-
dependently related to DFS (HR 6.85 [95% CI 1.98–23.68];
p¼0.002) in Cox regression multivariate analysis. There was no
signiﬁcant correlation with OS in this model.
Table 5
The effect of patient and tumor characteristics on overall and disease free Survival – Multivariate Cox Regression analysis.
Factors Disease-free survival Overall survival
Survival (n¼128) (n¼128)
HR 95%CI p HR 95%CI p
Any receptor change versus no change 6.847 1.980–23.676 0.002 3.056 0.673–13.885 0.148
Age: r40 versus 440 6.129 2.544–14.764 o0.001 4.542 1.758–11.735 0.002
Clinical stage:IIIB-C versus IIB-IIIA 1.985 0.911–4.325 0.084 2.131 0.893–5.083 0.088
Grade: III versus II 1.931 0.779–4.784 0.155 3.661 1.048–12.792 0.042
Lymphovascular invasion: yes versus no 6.345 2.119–18.995 0.001 6.912 1.516–31.509 0.012
Subtype: TNBC versus other 3.458 1.112–10.753 0.032 1.771 0.427–7.344 0.431
CT: anthracycline versus anthracyclineþtaxane 1.122 0.381–3.306 0.835 2.173 0.451–10.465 0.333
*po0.05; Cox regression; HR: Hazard Ratio; TNBC: triple negative breast cancer
V. Ozmen et al. / Cancer Treatment Communications 4 (2015) 89–95944. Discussion
Neoadjuvant chemotherapy is known to affect the hormone
receptor status, most commonly in a negative way [14–16,19,20].
With NAC becoming more commonly used as primary treatment
for LABC patients, questions about the stability of the ER, PR and
HER-2 receptors after NAC need to be addressed to optimize per-
sonalized adjuvant therapy.
Signiﬁcant effects of NAC on the expression of tumor biological
markers are controversially discussed, with some groups reporting
no changes and others observing changes of expression.[21–23] A
review of literature published in 2011 by van de Ven et al. revealed
that discordance of the hormone receptor status was reported in
four out of eight studies in 8-33% of the patients[15]. In a recent
large retrospective trial out of MD Anderson Cancer Center, Par-
inyanitikul et al. reported that 41% of a total of 398 women had a
change in at least one biomarker (ER, PR or HER2) [24]. In their
analysis, they found that any receptor change correlated with in-
creased relapse-free survival (p¼0.003), but no correlation with
OS was found. This positive correlation between receptor status
change and RFS is in contrast to our ﬁndings, as well as the ﬁnd-
ings of Chen et al. who reported that change in HR status was an
independent predictor for a poorer DFS as well as OS [20]. It
should be noted that in the MD Anderson study, the testing was
not central, though most cases were tested at MD Anderson and all
cases were reviewed by their pathologists. The authors com-
mented on the potential signiﬁcance of tumor evolution and clonal
selection due to tumor heterogeneity after exposure to therapy,
and implicated that such factors could be playing a role in the lack
of tumor biomarker stability. They emphasized that hormonal
therapy should not be withheld on the basis of post-NAC evalua-
tion after presenting their initial ﬁndings at San Antonio Breast
Cancer Symposium in 2013. We are also convinced that alteration
in HR status should not affect the decision for hormonal therapy
and we believe that patients who were found that have IHC po-
sitive for either ER or PR at any time-point should still be treated
with adjuvant hormonal therapy. Treatment implications of re-
ceptor status changes need to be further carefully evaluated in
larger multi-center trials that have been prospectively designed.
In our study, 128 patients had post-NAC tissue available for
paired analysis, and HR status was found to have changed in 28%
of patients (n¼36). Even though patient selection was done ret-
rospectively in a single institution, our study gains strength from
the fact that all pathologic analyses of paired samples were carried
out centrally by specialized breast pathology experts at Istanbul
University Department of Pathology, who work closely with of our
breast oncologists and surgeons.
Our Kaplan–Meier survival analysis and our multivariate model
were able to identify signiﬁcant relationships between HR altera-
tions and survival, indicating worse prognosis in terms or OS andDFS, respectively. Even though it is impossible to say whether our
ﬁndings could have has any treatment implications due trial de-
sign and sample size limitations, they may have signiﬁcant im-
plications regarding follow-up.
Finally, in our study, only 3% of the tumors switched from HER-
2 positive to HER-2 negative after NAC, which is slightly lower
than in most other studies of similar conduct. However, it should
be noted that in Turkey, neo/adjuvant use trastuzumab was ap-
proved after the cut-off date for this study and none of the patients
were exposed to trastuzumab. In a review of literature, switch to a
negative HER2 receptor status was reported in up to 43% of the
patients when NAC was combined with trastuzumab [15].5. Conclusion
HER-2 status as well as hormone receptors should be re-
evaluated on post-chemotherapy surgical specimens since changes
can be observed. The clinical relevance of these changes to ad-
juvant endocrine therapy or trastuzumab requires further long-
term follow-up and until such data becomes available, caution
should be exercised when basing adjuvant therapy regimens and
prognostication on pre-operative tumor marker studies alone.Conﬂicts of interest
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